Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Main Inclusion Criteria:

• • The patient is a man or woman aged ≥65 yrs
• The patient has Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™).
• The patient has an inadequate response to at least one adequate antidepressant treatment in the current Major Depressive Episode (MDE).
• The patient has had the current MDE for ≥8 weeks
• The patient is currently treated with a protocol specified ADT for at least 6 weeks
• The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator.
• Montgomery and Åsberg Depression Rating Scale (MADRS) total score > 18 at screening and baseline
• Clinical Global Impression - Severity (CGI-S) total score ≥3 at screening and baseline

Main Exclusion Criteria:

• • The patient has a clinically significant unstable illness
• The patient has newly diagnosed or unstable diabetes
• The patient has a Mini Mental State Exam (MMSE) score <24
• The patient has received Transcranial Magnetic Stimulation (TMS) and/or electroconvulsive therapy (ECT) less than 6 months prior to the Screening.
• The patient, in the opinion of the investigator or based on Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation and behaviour rating, is at significant risk of suicide

Other protocol defined inclusion and exclusion criteria may apply